Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial

Posted on by

Lancet Infectious Diseases
Feb 2021 Volume 21 Number 2 p149-296, e16-e35
https://www.thelancet.com/journals/laninf/issue/current

 

Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial
Guy de Bruyn, et al